- Home
- CATX vs MBX Comparison
CATX vs MBX Comparison
Compare CATX & MBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CATX
- MBX
- Stock Information
- Founded
- CATX 1983
- MBX 36
- Country
- CATX United States
- MBX United States
- Employees
- CATX N/A
- MBX N/A
- Industry
- CATX Medical/Dental Instruments
- MBX
- Sector
- CATX Health Care
- MBX
- Exchange
- CATX Nasdaq
- MBX NYSE
- Market Cap
- CATX 782.7M
- MBX 644.6M
- IPO Year
- CATX N/A
- MBX 2024
- Fundamental
- Price
- CATX $3.44
- MBX $9.89
- Analyst Decision
- CATX Strong Buy
- MBX Strong Buy
- Analyst Count
- CATX 9
- MBX 4
- Target Price
- CATX $17.25
- MBX $37.25
- AVG Volume (30 Days)
- CATX 1.2M
- MBX 373.3K
- Earning Date
- CATX 02-12-2025
- MBX 02-16-2025
- Dividend Yield
- CATX N/A
- MBX N/A
- EPS Growth
- CATX N/A
- MBX N/A
- EPS
- CATX N/A
- MBX N/A
- Revenue
- CATX $1,557,000.00
- MBX N/A
- Revenue This Year
- CATX N/A
- MBX N/A
- Revenue Next Year
- CATX N/A
- MBX N/A
- P/E Ratio
- CATX N/A
- MBX N/A
- Revenue Growth
- CATX N/A
- MBX N/A
- 52 Week Low
- CATX $2.70
- MBX $9.65
- 52 Week High
- CATX $19.10
- MBX $27.50
- Technical
- Relative Strength Index (RSI)
- CATX 41.92
- MBX N/A
- Support Level
- CATX $3.02
- MBX N/A
- Resistance Level
- CATX $3.74
- MBX N/A
- Average True Range (ATR)
- CATX 0.26
- MBX 0.00
- MACD
- CATX 0.16
- MBX 0.00
- Stochastic Oscillator
- CATX 60.90
- MBX 0.00
About CATX Perspective Therapeutics Inc.
Perspective Therapeutics Inc is a medical technology and radiopharmaceutical company that is pioneering various treatment applications for cancers throughout the body. The Company has a proprietary technology that utilizes the alpha emitting isotope 212Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides.
About MBX MBX BIOSCIENCES INC
MBX Biosciences Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include MBX 2109, MBX 1416, and MBX 4291.